Immune checkpoint blockade (ICB) improves survival in many types of cancers including
melanoma, non-small cell lung, renal cell, breast, and cervical cancers. However, many of …

Immune checkpoint blockade has revolutionized the treatment of multiple tumor types,
including melanoma and nonmelanoma skin cancers. The use of immune checkpoint …

The discovery of immune checkpoint inhibition (ICI) sparked a revolution in the era of
targeted anticancer therapy. However, although monoclonal antibodies targeting the …

New advancements in medicine have paved the way for targeted therapies and immune
checkpoint inhibitors (ICIs), which have become mainstays of cancer therapy. Targeted …

The development of immune checkpoint inhibitors (ICIs) has dramatically altered the
landscape of therapy for multiple malignancies, including urothelial carcinoma, non-small …

Breakthrough targeted therapies have produced significant improvements in survival for
cancer patients, but have a propensity to cause cutaneous immune‐related adverse events …

The introduction of immune checkpoint inhibitors (ICIs) has transformed the management of
various malignancies. Alongside their therapeutic success, the widespread application of …

The dermal delivery of peptide therapeutics that are of high molecular weight is a challenge.
Cyclosporine A (CsA) is a cyclic undecapeptide with poor aqueous solubility and high …

Diversos estudios sugieren que los pacientes con psoriasis tienen un mayor riesgo de
aparición de neoplasias, especialmente cutáneas, lo que podría estar asociado al uso de …

Background Cutaneous immune-related adverse events (irAEs) are the most common irAEs
caused by immune-checkpoint inhibitors (ICI). Psoriasiform eruptions, both de novo and …